Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation and Food Effect Study to Assess the Safety, Tolerance, and Pharmacokinetics of FZJ-003 In Healthy Volunteers

A randomized, double-blinding, dose-escalated phase 1 trial to evaluate the tolerance and fasting/postprandial pharmacokinetics of FZJ-003, an oral Janus kinase1 (JAK1) inhibitor.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteers
• Intervention / Treatment: Drug: FZJ-003; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 62
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Jilin
    • Changchun, Jilin, China, 130000
      • The First Bethune Hospital of Jilin University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Written informed consent；
2. Communicate well with the researcher and be able to complete the research in accordance with the research regulations；
3. No plan for pregnancy in the next 6 months and voluntarily take effective contraceptive measures; No plan for sperm or egg donation；
4. Healthy male and/or female subjects between the ages of 18 and 50 years ( inclusive)；
5. Male body weight≥50.0kg or female body weight≥45.0kg; Body Mass Index (BMI) between 18 to 28 (both inclusive), calculated as weight in kg / height in m2.

Exclusion Criteria:

1. Someone smoking more than 5 pieces per day within the 3 months before the trial；
2. Suspected of being allergic to investigational drug or any ingredient in the investigational drug, or people with allergies (multi-drug or food allergies)；
3. Having a history of alcohol abuse (14 units of alcohol per week: 1 units = beer 285 mL, or 25 mL of spirits, or 100 mL of wine);
4. Blood donation or extensive blood loss ≥400 mL within 3 months before screening, or planning blood donors during the study;
5. Urine drug test positive or have a history of drug abuse or drug use in the past 5 years;
6. Subjects who were intolerant of high-fat meals (2 boiled eggs, 1 slices of buttered bacon toast, a box of fries, and a glass of whole milk) were applied only to subjects who participated in the postprandial test;
7. Taked any drug within 14 days before screening, including prescription drugs, over-the-counter drugs, Chinese herbal medicines and health products (except regular supplementary vitamins);
8. Taked any drug that changes liver drug enzyme activity within 28 days before screening, such as CYP3A4 inhibitors or inducers;
9. Major changes in diet or exercise habits within 2 weeks before screening or during the period from screening to administration;
10. Took a special diet (including dragon fruit, mango, grapefruit, etc.) or strenuous exercise, and other activities that affect drug absorption, distribution, metabolism, excretion and so on within 2 weeks before screening;
11. Received or planned to receive any vaccine within 30 days before and after the trial;
12. Participated in clinical trials within 3 months before the first administration of the study, or planned to participate in other clinical trials during the study period;
13. Having difficulty of swallowing or any history of gastrointestinal diseases that affect drug absorption;
14. With low immune function or immunodeficiency, or long-term use of immunosuppressive drugs; or used immunosuppressive drugs within 30 days before screeing;
15. Have or have had malignant tumors；
16. Active tuberculosis; or have a history of tuberculosis or latent tuberculosis infection; tuberculosis infection T cell spot test positive;
17. Any infection that has been determined to be clinically significant by the investigator within 3 months or any infection within 7 days before the study;
18. Herpes or varicella within 3 months before the trial;
19. Underwent major trauma or major surgery in 3 months before screening, or have plan for surgery in trial;
20. Have a history of diverticulitis, peptic ulcer or perforation of digestive tract；
21. Clinical laboratory tests are abnormal and have clinical significance, or other clinical findings showing clinically significant diseases (including but not limited to heart Cerebrovascular, gastrointestinal, lungs, endocrine, renal, nerves, blood, immunizations, or mental disease);
22. Active viral hepatitis (B or C) as demonstrated by positive serology at Screening；or test positive for human immunodeficiency virus (HIV) at Screening; or syphilis treponema pallidum antibody and syphilis rapid plasma reagin test are positive;
23. QTcB interval greater than (>) 470 (male) or 480 (female) milliseconds;
24. Female subjects are in lactation or serum pregnancy test are positive during screening or during the test;
25. Acute illness or combination therapy from the screening stage to administration;
26. Taking chocolate, any caffeine, or xanthine-rich food or drink at least 48 hours prior to the use of the study drug;
27. Taking any alcoholic products within 24 hours prior to the use of the study drug, or cannot limit alcohol drinks as required in trial;
28. Other circumstances that is deemed not appropriate for the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Subjects will receive placebo oral capsules (matching FZJ-003) in a dose escalation format .
Experimental: FZJ-003	Drug: FZJ-003; Subjects will receive FZJ-003 oral capsules in a dose escalation format.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events and the number of volunteers with adverse events as a measure of safety and tolerability	Tests will be performed to assess whether the study drug has any potentially adverse effect (laboratory tests on blood and urine for functioning of organs; ECG testing). Also, participants will carefully be monitored by medical staff for vital signs, and asked to report any side effect experienced in the course of the study.	up to 72 hours postdose

Secondary Outcome Measures

Outcome Measure	Time Frame
Maximum Plasma Concentration (Cmax)	up to 72 hours postdose
Area under the plasma concentration-time curve (AUC)	up to 72 hours postdose
Pharmacodynamics (PD) parameters of percent and actual change from baseline for a panel of JAK-dependent biomarkers	up to 24 hours postdose

Collaborators and Investigators

• Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): January 27, 2021
• Primary Completion (Actual): July 13, 2022
• Study Completion (Actual): July 13, 2022

Study Registration Dates

• First Submitted: January 19, 2021
• First Submitted That Met QC Criteria: January 19, 2021
• First Posted (Actual): January 20, 2021

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 10, 2025
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: F0025-101

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No